1. Opening remarks

   Serotonin and Vascular Disease Pages: 5 - 5

2. Editorial introduction

   Focused Section: Angiotensin Converting Enzyme Inhibition: Renal Aspects Pages: 195 - 195

3. Serotonergic antagonists and vascular disease

   • Paul M. Vanhoutte

   Serotonin and Vascular Disease Pages: 7 - 12

4. Introduction to focused issue

   • John H. Bauer

   Focused Section: Angiotensin Converting Enzyme Inhibition: Renal Aspects Pages: 197 - 197

5. Serotonin antagonists and vascular protection

   • Austin E. Doyle

   Serotonin and Vascular Disease Pages: 13 - 18

6. Angiotensin converting enzyme inhibitors: Comparative structure, pharmacokinetics, and pharmacodynamics

   • Gurdarshan S. Thind

   Focused Section: Angiotensin Converting Enzyme Inhibition: Renal Aspects Pages: 199 - 206

7. Serotonin and acute cardiovascular disorders

   • Robert S. Reneman
   • Pieter J. A. van der Starre

   Serotonin and Vascular Disease Pages: 19 - 25

8. Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney

   • Garry P. Reams
   • John H. Bauer

   Focused Section: Angiotensin Converting Enzyme Inhibition: Renal Aspects Pages: 207 - 219

9. Central serotonergic mechanisms in cardiovascular regulation

   • Jane Minson
   • John Chalmers
   • Paul Pilowsky

   Serotonin and Vascular Disease Pages: 27 - 32

10. Renal effects of angiotensin converting enzyme inhibitors: Nondiabetic chronic renal disease

    • John A. Opsahl
    • Paul A. Abraham
    • William F. Keane

    Focused Section: Angiotensin Converting Enzyme Inhibition: Renal Aspects Pages: 221 - 228

11. Portal hypertension: Serotonin and pathogenesis

    • Didier Lebrec

    Serotonin and Vascular Disease Pages: 33 - 35

12. ACE inhibitors in renovascular hypertension

    • Stephen C. Textor

    Focused Section: Angiotensin Converting Enzyme Inhibition: Renal Aspects Pages: 229 - 235

13. The role of serotonin in the preeclampsia-eclampsia syndrome

    • Carl P. Weiner

    Serotonin and Vascular Disease Pages: 37 - 43

14. Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension

    • Gary H. Gibbons
    • Victor J. Dzau

    Focused Section: Angiotensin Converting Enzyme Inhibition: Renal Aspects Pages: 237 - 242

15. Pathogenesis and treatment of Raynaud's phenomenon

    • Jay D. Coffman

    Serotonin and Vascular Disease Pages: 45 - 51

16. Cardiac effects of angiotensin converting enzyme inhibitors

    • Norman Sharpe

    Focused Section: Angiotensin Converting Enzyme Inhibition: Renal Aspects Pages: 243 - 245

17. Carcinoid syndrome and serotonin: Therapeutic effects of ketanserin

    • J. Ian S. Robertson

    Serotonin and Vascular Disease Pages: 53 - 58

18. Mechanisms of nitrate tolerance: A review

    • Richard J. Katz

    Review Pages: 247 - 252

19. 5-Hydroxytryptamine induces contraction in isolated human mammary artery: Effect of ketanserin

    • Angela Monopoli
    • Annamaria Conti
    • Paolo Biglioli

    Pharmacology of Serotonin and Serotonin Antagonists Pages: 59 - 61

20. Felodipine in the treatment of patients with severe hypertension and impaired renal function

    • R. Larsson
    • M. K. Lindsjö
    • L. Moberg

    Hypertension Pages: 253 - 259

21. Evidence for a direct and non-receptor-mediated action of 5HT₂ antagonists on transmembrane cation transport systems

    • Leonardo Alberto Sechi
    • Rinaldo Tedde
    • Alessandra Melis

    Pharmacology of Serotonin and Serotonin Antagonists Pages: 63 - 67

22. A double-blind comparison of bisoprolol and captopril for treatment of essential hypertension in the elderly

    • Daniele Bracchetti
    • Roberto Gradnik
    • Ivano Cantelli

    Hypertension Pages: 261 - 264

23. Effects of ketanserin tartrate on 3-hydroxy, 3-methylglutaryl coenzyme a reductase activity in cultured human skin fibroblasts

    • Michio Suzukawa
    • Haruo Nakamura

    Pharmacology of Serotonin and Serotonin Antagonists Pages: 69 - 72

24. Effect of enalapril on parasympathetic activity

    • E. Boni
    • C. Alicandri
    • G. Muiesan

    Hypertension Pages: 265 - 268

25. Effects of ketanserin of left ventricular hypertrophy in hypertensive patients

    • Carlos Cobo
    • Luis Alcocer
    • Alejandro Chávez

    Clinical Pharmacology Pages: 73 - 76

26. Porcine heparin increases postoperative bleeding in cardiopulmonary bypass patients

    • Leigh I. G. Iverson
    • Francis G. Duhaylongsod
    • Ivan A. May

    Clinical and Basic Pharmacology Pages: 269 - 272

27. Regression of left ventricular hypertrophy and systolic function in hypertensive patients during long-term treatment with ketanserin

    • Vincenzo Coto
    • Manlio Cocozza
    • Luigi Cacciatore

    Clinical Pharmacology Pages: 77 - 80

28. Vasodilatory effects of nisoldipine on coronary arteries—Correlation with plasma levels

    • Stefan Jost
    • Wolf Rafflenbeul
    • Paul R. Lichtlen

    Clinical and Basic Pharmacology Pages: 273 - 279

29. Left ventricular hypertrophy regression and function changes with ketanserin in elderly hypertensives

    • Gregory P. Vyssoulis
    • Eva A. Karpanou
    • Pavlos K. Toutouzas

    Clinical Pharmacology Pages: 81 - 84

30. Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy

    • Alessandro Capucci
    • Giuseppe Boriani
    • Bruno Magnani

    Clinical and Basic Pharmacology Pages: 281 - 287

31. Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failure

    • Stephan Brune
    • Thomas Schmidt
    • Heinrich Kreuzer

    Clinical Pharmacology Pages: 85 - 87

32. Plasma concentrations of atrial natriuretic peptide during physical exercise in patients with congestive heart failure

    • Markus Haass
    • Rainer Dietz
    • Wolfgang Kübler

    Clinical and Basic Pharmacology Pages: 289 - 295

33. Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?

    • Susan E. Gould
    • Joseph H. Silas
    • James Hosie

    Clinical Pharmacology Pages: 89 - 92

34. Drag-reducing polymers: A novel class of diuretic and natriuretic compounds

    • Donald David Symth
    • Philip Iniziato Polimeni

    Clinical and Basic Pharmacology Pages: 297 - 300

35. The effects of ketanserin on ventricular ectopic activity in humans

    • Christine Marks
    • Ian Dews
    • Malcolm VandenBurg

    Clinical Pharmacology Pages: 93 - 95

36. Letter: Calcium and blood pressure

    • R. B. Singh

    Clinical and Basic Pharmacology Pages: 301 - 301

37. Effects of ketanserin on intraocular pressure

    • Ciro Costagliola
    • Maria Lusia Fasano
    • Liberato Aldo Ferrara

    Clinical Pharmacology Pages: 97 - 99

38. Letter: Interaction between morphine and granulocyte aggregation in mycardial ischaemia

    • Antonino Mazzone
    • Giovanni Riceenti

    Clinical and Basic Pharmacology Pages: 303 - 304

39. Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension

    • Masato Konishi
    • Muneki Sakakura
    • Nobuko Tsushima

    Clinical Pharmacology Pages: 101 - 104

40. Impaired uptake of 5 hydroxytryptamine platelet in essential hypertension: Clinical relevance

    • Natalia Fetkovska
    • Alfred Pletscher
    • Fritz R. Buhler

    Clinical Pharmacology Pages: 105 - 109

41. Oral dosing with ketanserin to control high blood pressure in the elderly

    • Joop C. van Oene

    Ketanserin in Acute Hypertension Pages: 111 - 114

42. A placebo-controlled crossover study of ketanserin in elderly hypertensive patients

    • Sean T. McCarthy
    • Gail L. McCarthy
    • Susan E. Gould

    Ketanserin in Acute Hypertension Pages: 115 - 117

43. Ketanserin and captopril interaction in the treatment of essential hypertensives

    • Giancarlo Lavezzaro
    • Pier Emilio Ladetto
    • Antonio Salvetti

    Ketanserin in Acute Hypertension Pages: 119 - 122

44. Comparison of ketanserin and enalapril in the treatment of mild-to-moderate essential hypertension

    • Lorenzo S. Malatino
    • Benedetta Stancanelli
    • Giacomo Tamburino

    Ketanserin in Acute Hypertension Pages: 123 - 126

45. Serotonin antagonism reduces the adverse symptoms of beta blockade

    • Krishnarao Korlipara
    • Susan E. Gould
    • Anthony Chandler

    Ketanserin in Acute Hypertension Pages: 127 - 131

46. Effect of ketanserin on pain perception in arterial hypertension

    • Caterina Rosa
    • Sergio Ghione

    Ketanserin in Acute Hypertension Pages: 133 - 135

47. Closing remarks serotonin and vascular disease: A survey

    • P.M. Vanhoutte

    Ketanserin in Acute Hypertension Pages: 137 - 140

48. Abstract translations from Symposium on Serotonin and Vascular Disease

    Abstract Pages: 141 - 187